Skip to main content
. 2019 Sep;8(5):2187–2191. doi: 10.21037/tcr.2019.08.26

Figure 2.

Figure 2

Target NGS of the tumor tissues or the cfDNA samples from plasma to monitor the genomic changes of the tumor during the treatment course. Liquid biopsies were performed at different time point during TKI treatment after the patient acquired resistance to crizotinib. *, published data. NGS, next generation sequencing; TKI, tyrosine kinase inhibitor; PD, progressive disease.